Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 942 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07600736RecruitingPhase 2
Safety study of ABS-1230 for children with KCNT1 epilepsy
This trial tests a new drug called ABS-1230 in children and young adults with KCNT1-related epilepsy, a rare genetic form of epilepsy. The study will check if the drug is safe and if it helps reduce seizures.
Hackensack, New JerseyAges 1 month–21 years - NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT07424404RecruitingPhase 3
Long-term safety study of a medication for psychiatric disorders in children and teens
This study tests a combination medicine (xanomeline and trospium chloride) to see if it is safe and tolerable over a longer period for children and adolescents with psychiatric disorders, especially those with autism-related irritability. It may help families understand if this treatment can be used beyond the initial study period.
Dothan, AlabamaAges 5–17 - NCT05086003RecruitingPhase 2
Kidney transplant with stem cell treatment to build immune tolerance
This Phase 2 study tests a combined treatment—kidney transplant plus stem cell–based immune therapy—to help the body accept the new kidney with less immune attack. You may be able to take part if you have a matching sibling donor and meet key safety and health requirements.
Petah TikvaAges 18–65 - NCT05338931RecruitingPhase 1/Phase 2
AT101 for relapsed or refractory B-cell lymphoma patients
This trial studies AT101 to see how safe it is, what side effects it causes, and whether it can help people with B-cell non-Hodgkin lymphoma that has come back or did not respond to treatment. It may be an option if your usual treatments are no longer working or aren’t suitable for you.
SeoulAges 19 years+ - NCT05528055RecruitingPhase 1
Safety study of SCR-6920 for advanced cancers
This Phase 1 trial tests whether SCR-6920 capsules are safe and tolerable in people with advanced, treatment-resistant cancers. It may help doctors learn the right way to dose the medicine and check for side effects.
Jinan, ShandongAges 18–75 - NCT05847465Recruiting
Testing body heat regulation after heat stroke in soldiers
This study looks at how well the body controls temperature during exercise after a past heat-stroke episode, in a military setting. It may help improve safety and recovery plans for people who have had exercise-related heat stroke.
Brétigny-sur-OrgeAges 18 years+ - NCT06097065Recruiting
Finding diabetes and prediabetes markers in blood and urine
This study looks at leftover blood and urine samples to find new markers that could help detect prediabetes and diabetes earlier. It may lead to better testing and management.
Guangzhou, GuangdongAges Any age - NCT05683717RecruitingPhase 1
First-dose test of TT-01488 for B-cell cancers
This Phase 1 study tests whether TT-01488 is safe and tolerable in people with B-cell malignancies (blood cancers). It’s meant for patients whose disease has come back or did not respond after standard treatments.
Nanjing, JiangsuAges 18 years+ - NCT05650242RecruitingPhase 1
Study of BA1106 in people with advanced solid tumors
This study tests an experimental drug called BA1106 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe, tolerable, and whether it can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07867288RecruitingPhase 1
Study of an investigational drug for non-obstructive hypertrophic cardiomyopathy
This trial tests an investigational drug given as an injection under the skin for people with a type of hypertrophic cardiomyopathy that does not block blood flow out of the heart. The goal is to see if the drug is safe and may help improve symptoms.
Kansas City, MissouriAges 18–70 - NCT04557462RecruitingPhase 3
Long-term safety study of iptacopan for IgA nephropathy
This study provides continuing treatment with iptacopan for people with IgA nephropathy who have completed a previous iptacopan trial. It aims to see how safe and tolerable the drug is over a longer period.
Glendale, ArizonaAges 18–100 - NCT06225804RecruitingPhase 1
Study of ABSK112 for advanced non-small cell lung cancer
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
Beverly Hills, CaliforniaAges 18 years+ - NCT06396871Recruiting
Blood cell study in metabolic diseases
This study looks at blood cells and factors in people with metabolic diseases like fatty liver, prediabetes, or type 2 diabetes. It aims to better understand these conditions by comparing them with healthy volunteers.
Dresden, SaxonyAges 18 years+ - NCT05579275RecruitingEarly Phase 1
Study JCXH-212 to treat advanced solid tumors safely
This early trial tests whether JCXH-212 alone, or with toripalimab (an immunotherapy drug), is safe and tolerable in people with advanced solid cancers. It also looks at whether treatment can help by targeting tumor “neoantigens” found in your tumor tissue.
Beijing, Beijing MunicipalityAges 18–75 - NCT07852156Recruiting
Cooling during inpatient rehabilitation for people with multiple sclerosis
This trial tests whether cooling the body during a stay at a rehabilitation clinic helps people with multiple sclerosis (MS) feel better and recover more effectively. If you have MS and find that heat makes your symptoms worse, this study may help you manage your symptoms during rehab.
Valens, Canton of St. GallenAges 18 years+ - NCT07842640RecruitingPhase 1
Injectable treatment for overweight and obesity
This study tests an injectable medication called ASC35 to see if it is safe and tolerable for people who are overweight or obese. It may help with weight management, though it is an early-stage trial focused on safety first.
Baltimore, MarylandAges 18–65 - NCT07848334RecruitingPhase 1
Study of OPF-110 in healthy adults
This study tests a new medicine called OPF-110 to see if it is safe and tolerable in healthy adults. It will help determine if further testing in patients is possible.
Anaheim, CaliforniaAges 18–64 - NCT07827144RecruitingPhase 1
Testing a new drug for advanced solid tumors
This study tests a new drug, BI 4060107, in people with advanced solid tumors. It is a phase 1 trial to find a safe dose and see how well people tolerate it, potentially offering a new option when standard treatments have stopped working.
Irving, TexasAges 18 years+ - NCT07827014Recruiting
Protein shake study for healthy adults
This study tests a daily protein shake in two flavors to see how well people tolerate it and if it affects their well-being. You would drink it once a day for 15 days and answer some questionnaires.
Carlsbad, CaliforniaAges 21–65 - NCT06478537RecruitingPhase 2
Hetrombopag for Immune Tolerance in ITP After Platelet Recovery
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
Beijing, Beijing MunicipalityAges 18–50 - NCT07815678RecruitingPhase 1/Phase 2
Safety study of an oral medication in people with normal or higher weight
This study tests a new oral medication called ACCG-2671 to see how safe it is and how your body handles it. It's an early-stage trial, so the main focus is on safety and tolerability. The study has different parts: one for people with normal weight and one for people with higher weight who are already taking a GLP-1 injection for weight loss.
Cypress, CaliforniaAges 25–75 - NCT07817251RecruitingPhase 3
Switching From Semaglutide to Cagrisema in Type 2 Diabetes
This study looks at how people with type 2 diabetes tolerate switching from a weekly semaglutide injection (like Ozempic or Wegovy) to a new experimental medicine called Cagrisema. The goal is to see if the switch is safe and effective.
Gilbert, ArizonaAges 18 years+
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 942 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.